OSI-930 ANALOGUES AS NOVEL REVERSAL AGENTS FOR ABCG2-MEDIATED MULTIDRUG RESISTANCE

OSI-930, a dual c-Kit and KDR tyrosine kinase inhibitor, is reported to have undergone a Phase I dose escalation study in patients with advanced solid tumors. A series of fifteen pyridyl and phenyl analogues of OSI-930 were designed and synthesized. Extensive screening of these compounds led to the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kuang, Ye-Hong, Patel, Jay P., Sodani, Kamlesh, Wu, Chun-Pu, Liao, Li-Qiu, Patel, Atish, Tiwari, Amit K., Dai, Chun-Ling, Chen, Xiang, Fu, Li-Wu, Ambudkar, Suresh V., Korlipara, Vijaya L., Chen, Zhe-Sheng
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3443622/
https://ncbi.nlm.nih.gov/pubmed/22750060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2012.06.019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados